In humans, the expression of SIRT5 is downregulated in the liver from patients with NAFLD, strengthening the connection between SIRT5 deficiency and defective β-oxidation of fatty acids [71]. Here, SIRT5 is linked to metabolic dysfunction-associated steatotic liver disease.